Related Experiment Videos
Pediatric headache
1Dallas Pediatric Neurology Associates, Dallas, Texas, USA.
Insights
Pediatric headaches can be disabling. Research into acute migraine treatments like serotonin agonists and preventive therapies is ongoing, aiming to improve diagnosis and management for better long-term outcomes.
Area of Science:
- Pediatric Neurology
- Headache Medicine
Background:
- Headaches are common and can be disabling in children and adolescents.
- Existing disability scales, like the MIDAS scale, have been adapted for pediatric use.
- Epidemiology and classification of pediatric headaches are receiving increased attention.
Purpose of the Study:
- To review current understanding and treatment of headaches in children and adolescents.
- To highlight the need for further research into effective therapies.
- To emphasize the link between childhood headaches and adult chronic daily headaches.
Main Methods:
- Review of existing studies on pediatric headache epidemiology, classification, and treatment.
- Discussion of current research on acute migraine treatments, including serotonin 1B/1D agonists.
- Mention of ongoing and planned studies on preventive therapies.
Main Results:
- Serotonin 1B/1D agonists show efficacy in treating acute migraine in adolescents, despite a high placebo response.
- Sumatriptan nasal spray is anticipated for FDA approval in adolescents.
- No single "wonder drug" currently exists for pediatric headaches.
Conclusions:
- Improved diagnostic criteria, early diagnosis, and effective treatments are crucial for managing pediatric headaches.
- Understanding the origins of adult chronic daily headaches may lie in childhood and adolescent onset.
- Continued research is essential to address remaining questions and improve patient outcomes.
Abstract:
Headaches are frequent in children and adolescents and at times can be extremely disabling. Disability scales, such as the MIDAS scale, have been useful in helping follow adult patients. Modifications of this scale have been helpful in following pediatric and adolescent patients. Greater attention has been paid to epidemiology and classification of headache in children. Studies are being done on serotonin 1B/1D agonist for treating acute migraine, and this agent has been found to be efficacious despite a high placebo response. It is anticipated that FDA approval of sumatriptan nasal spray in adolescents is forthcoming. Despite advancements, there is no wonder drug. There continues to be a need for studying preventive therapies in a double-blind, placebo-controlled environment, and plans are under way for such studies. Many adult patients with chronic daily headaches report that their headaches began in childhood and adolescence. A better understanding of diagnostic criteria, early diagnosis, and more effective treatment may be the key to influencing the prevalence of headaches in adults. Continued research is the only answer to the questions raised by the most recent studies in this population.